Filippo Pietrantonio, Head of the Gastrointestinal Oncology Unit at Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, shared Annals of Oncology’s post on X, adding:
“This is a very important study and I am extremely happy to see these results published! It’s a symbolic demonstration that immunotherapy can make it even in phase 3 setting regardless of rarity of the disease or for difficult and hard to treat populations with risk for disparity.”
Quoting Annals of Oncology’s post:
“POD1UM-303 updated: Retifanlimab + Carbo/Tax improved PFS (9.3 vs 7.4 m) and OS (32.8 vs 22.2 m; HR 0.75) in 1L advanced SCAC, supporting a new standard of care.”
Title: Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin–paclitaxel in first-line advanced squamous anal cancer
Authors: S. Rao, E. Samalin-Scalzi, L. Evesque, M. Ben Abdelghani, F. Morano, A. Roy, L. Dahan, S. Tamberi, A.S. Dhadda, M.G. Zampino, N. Casanova, R. Guimbaud, A. Lievre, J. Maurel, P. Zhang, M.C. Munteanu, M. Jones, C. de la Fouchardiere, A. Takashima, M. Fakih, J. Spano
Other articles featuring Filippo Pietrantonio and Annals of Oncology on OncoDaily.
